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Abstract
Background: Biomarkers released from the heart at early stage of ischemia are very important to diagnosis of
ischemic heart disease and salvage myocytes from death. Known specific markers for blood tests including CK-MB,
cardiac troponin T (cTnT) and cardiac troponin I (cTnI) are released after the onset of significant necrosis instead of
early ischemia. Thus, they are not good biomarkers to diagnose myocardial injury before necrosis happens.
Therefore, in this study, we performed proteomic analysis on effluents from perfused human hearts of donors at
different ischemic time.
Results: After global ischemia for 0 min, 30 min and 60 min at 4°C, effluents from five perfused hearts were
analyzed respectively, by High performance liquid chromatography-Chip-Mass spectrometry (HPLC-Chip-MS)
system. Total 196 highly reliable proteins were identified. 107 proteins were identified at the beginning of
ischemia, 174 and 175 proteins at ischemic 30 min and ischemic 60 min, respectively. With the exception of
cardiac troponin I and T, all known biomarkers for myocardial ischemia were detected in our study. However, there
were four glycolytic enzymes and two targets of matrix metalloproteinase released significantly from the heart
when ischemic time was increasing. These proteins were L-lactate dehydrogenase B(LDHB), glyceraldehyde-3-
phosphate dehydrogenase, glucose-6-phosphate isomerase (GPI), phosphoglycerate mutase 2 (PGAM2), gelsolin
and isoform 8 of titin. PGAM2, LDHB and titin were measured with enzyme-linked immunosorbent assays kits. The
mean concentrations of LDHB and PGAM2 in samples showed an increasing trend when ischemic time was
extending. In addition, 33% identified proteins are involved in metabolism. Protein to protein interaction network
analysis showed glycolytic enzymes, such as isoform alpha-enolase of alpha-enolase, isoform 1 of triosephosphate
isomerase and glyceraldehyde-3-phosphate dehydrogenase, had more connections than other proteins in
myocardial metabolism during ischemia.
Conclusion: It is the first time to use effluents of human perfused heart to study the proteins released during
myocardial ischemia by HPLC-Chip-MS system. There might be many potential biomarkers for mild ischemic injury
in myocardium, especially isoform 8 of titin and M-type of PGAM2 that are more specific in the cardiac tissue than
in the others. Furthermore, glycolysis is one of the important conversions during early ischemia in myocardium.
This finding may provide new insight into pathology and biology of myocardial ischemia, and potential diagnostic
and therapeutic biomarkers.
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Ischemic Heart Disease (IHD) is the most common
cause of death and a major cause of hospital admissions
in most Western countries [1]. The diagnosis of IHD is
based on particular symptoms, an electrocardiogram, an
X-ray of the chest and blood tests. Reasonably specific
markers for blood tests including creatine kinase mus-
cle/brain isoform (CK-MB), cardiac troponin T (cTnT)
and cardiac troponin I (cTnI) are released after the
onset of significant necrosis instead of early ischemia,
and they all require a level of myocardial necrosis to
prompt their release from myocytes before they can be
detected. Those biomarkers are impossible to be
detected at early stage of ischemia and the diagnosis of
IHD is often ambiguous. On the other hand, it is impos-
sible to salvage dead myocytes at the stage of necrosis
when specific markers such as CK-MB, cTnT and cTnI
are detected. Thus, biomarkers detectable before the
onset of significant necrosis would be more important
than those in current use. Evidence has shown that mar-
kers released upon initiation of ischemia alone may exist
[2-4]. If it is true, such markers would offer the oppor-
tunity for early diagnosis of IHD before permanent myo-
cyte damage occurs, which will allow possible salvage of
the myocardium by timely reperfusion. However, it is
very difficult to discover a novel biomarker by screening
t h ee n t i r ep r o t e o m eo fp l a s m af r o mt h eI H Dp a t i e n t s
[ 4 , 5 ] .T h i si sb e c a u s et h e r ea r em a n yh i g h l ya b u n d a n t
proteins present in the serum or plasma, which will
mask biomarkers, presumably the less abundant pro-
teins. Proteomic analysis of the plasma from patients
with acute coronary syndromes (ACS) revealed only five
differentially expressed proteins, all of which were highly
abundant plasma proteins [6]. Thus, it is very important
to eliminate the interference by highly abundant plasma
proteins. Isolated perfused heart effluent is a novel
model for protein biomarker discovery. This model dis-
penses with most highly abundant proteins in blood [7].
In our study, effluents from human perfused heart for
transplantation at different ischemic time points were
collected for proteomic analysis to identify potential
ischemic biomarkers.
Materials and methods
Effluent collection and concentration
The study protocol was approved by the Ethics review
board of the Third Military Medical University. The
effluent samples were collected from human donor’s
hearts for transplantation. Five donors were brain dead
due to car accident, their respiration was maintained by
mechanical ventilation and hemodynamics was stabilized
by minimum doses of catecholamine. The donors with
normal cardiac function were brought into our study.
The donors with sustained (> 5 min) profound hypoten-
sion (≤ 50 mmHg on systolic pressure), cardiac arrest,
intracardiac injection and history of heart disease or
heart injury due to thoracic trauma, diabetes mellitus,
hypertension, coronary arterial disease were excluded.
CK-MB and cTnI in serum were measured before the
operation for harvesting the heart. Clinical characteris-
tics are shown in Table 1.
The operation of the donor heart dissection was per-
formed with a standard procedure. Briefly, the patients
were anesthetized with isoflurane, intubated and ventilated
with 100% oxygen. The heart and great vessels were
exposed after sternotomy. Heparin at 3 mg/kg was
injected intravenously for systemic anticoagulation. After a
cardioplegic cannula was placed into the ascending aorta,
one liter of a hypothermic (4°C) hyperkalemic crystalloid
solution (composition in mmol/L: Na + 127, K + 20, Mg2
+ 8, Cl- 20, SO4 - 8, HCO3 - 20, pH 7.9) was infused into
the aortic root to achieve cardioplegic arrest. After cardio-
plegic infusion, the donor heart was extracted and placed
in a basin containing 2000 ml cardioplegia solution at 4°C,
The cardioplegic cannula and aortic cross-clamp were left
in place to permit perfusion. Then, hypothermic cardiople-
gia was infused continually through the cardioplegic can-
nula until there was no blood in the effluent judged by
eyes. A catheter was placed from inferior vena entrance
into the exit of coronary sinus. The catheter was fixed and
these open ends of superior and inferior vena, pulmonary
arteries and veins were clamped. 200 ml hypothermic car-
dioplegia was infused into aortic root within 2 min and
the effluent from the coronary sinus was collected into the
50 ml polypropylene tubes as the sample for the first time
point. Finally, the heart was placed in a bag, and stored on
ice. After 30-min ischemia, 200 ml cold cardioplegia was
infused through the cardioplegic cannula, effluent was col-
lected for the second time point. After ischemia for 60
min, effluent was collected again as the sample for the
third time point. The effluent samples from each of the 5
hearts were mixed with protease inhibitors (1.67 mL of
100 mM NaN3, 2.5 mL of 11.5 mM PMSF) to avoid pro-
teolysis and then cell debris and insoluble solids were
removed by centrifugation at 10 000 × g for 15 min at 4°C.
The precipitates were removed and then the supernatants
were concentrated by using the Amicon Ultra-15 3 kDa
Table 1 Clinical information of the five heart donors
No. Sex Age Blood type CK-MB (ng/mL) cTNI (ng/mL)
1 M 36 B 12 –
2 M 28 AB 22 –
3 M 32 O 16 –
4 F 35 A 11 –
5 F 32 B 13 –
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protein was stored at -80°C for further analysis.
Removal of High-Abundance Proteins
All procedures of removing high-abundance proteins
were performed according to manufacturer’si n s t r u c -
tions. Briefly, each effluent sample was thawed and cen-
trifuged at 10 000 × g for 30 min at 4°C. Multiple
affinity removal system 4.6 × 50 Hu-7 (5188-6409, Agi-
lent Technologies) was used to remove high-abundance
proteins from the effluent samples according to a stan-
dard liquid chromatography protocol. Briefly, the sample
was diluted three times with Buffer A and centrifuged at
16 000 g for 10 min. The diluted sample was used for
injection at a flow rate of 0.25 ml/min. The low-abun-
dance protein fraction from 1.5 min to 4.5 min was col-
lected into a 1.5 ml Eppendorf tube and store at 4°C for
further analysis, and the high-abundance protein frac-
tion was eluted with Buffer B at a flow rate of 1.0 ml/
min, then the column was regenerated with buffer A.
Protein concentrating and desalting
The low-abundance proteins were then concentrated
and desalted by using the Amicon Ultra-15 10 kDa
MWCO centrifugal filters (Millipore) according to man-
ufacturer’s instructions. Briefly, 10 ml of low-abundance
fraction was filled into five spin concentrators with 10
kDa molecular weight cutoff. The samples were spun at
14 000 g for 30 min at 4°C, the filtrate was discarded,
the concentrated protein was kept, and then the concen-
trator was refilled with an appropriate buffer (8 M urea)
and spun again. After repeating this procedure three
times, the sample was collected. Protein content was
determined by using Bradford assay kit (Thermo, USA)
and the sample was aliquoted into 40 ug fractions.
In-solution tryptic digestion
In-solution tryptic digestion was performed according to
the standard protocol provided by Agilent Technologies.
Briefly, the Eppendorf tube contained 40 ug protein was
added to 10 μl of 10 mM dithiothreitol (DTT) and incu-
bated for 1 h at 56°C. After 20 μl of 20 mM iodoaceta-
mide (IAM) was added, the Eppendorf tube was placed
in dark for 1 h at room temperature. Then, 10 μlo f1 0
mM DTT was added again to quench the excess IAM
for 1 h at 37°C. Protein was digested by 40 μlt r y p s i n
(12.5 ng/μL) (Sequencing Grade, Promega, USA) for 12
h at 37°C. Finally, the reaction was terminated by adding
2.5 μl formic acid.
High performance liquid chromatography-Chip-Mass
spectrometry (HPLC-Chip-MS) system analysis
The sample was analyzed on an Agilent 1200 HPLC and
6330 Ion Trap system (Agilent technologies, USA) as
described previously [8-10]. 1 μl of digests (400 ng)
were injected on a Zorbax chip composed of an enrich-
ment column (560.3 mm, 5 mm particles) and a Zorbax
300SB C18 (75 μm × 150 mm, 3.5 mm particles) analy-
tical column. The mobile phase for both capillary pump
and nanopump consisted of 0.1% formic acid in distilled
water (A) and 0.1% formic acid in 90/10 acetonitrile/dis-
tilled water (B). The flow rate for the capillary pump
w a sh e l dc o n s t a n ta t4μl/min in 3% B (isocratic) while
t h ef l o wr a t ef o rt h en a n o p u m pw a s0 . 3μl/min, follow-
i n gag r a d i e n to f3-7 5 %Bi n7 0m i n .T h em a s ss p e c -
trum was operated in chip positive ionization mode,
with voltage at 4 KV, drying gas temperature at 325°C
and drying gas flow at 6 L/min. In-source voltage was
set at 1850 V, capillary exit at 96.4 V, skimmer at 40 V,
end plate offset at -500 V. Automatic MS/MS in a data-
dependent manner was acquired in enhanced mode at
m/z 200 - 1600. Due to statistical fluctuations of peptide
precursor selection during MS/MS acquisition, three
LC-MS/MS assays were run with each sample in order
to be able to do a proper proteomic comparison.
Enzyme-linked immunosorbent assays (ELISA)
The concentration of three interested proteins identified
by MS was quantitatively determinated with phosphogly-
cerate mutase 2(PGAM2) human ELISA kit (Cusabio
biotech CO., LTD, China), L-lactate dehydrogenase B
(LDHB) human ELISA kit and titin human ELISA kit
(Uscn Life Science Inc, China) according to the manufac-
turer’s instructions in a blinded manner. Optical densities
were measured at 450 nm by an eight-channel spectro-
photometer. The concentration of LDHB, PGAM2 and
titin was calculated using respective assay standard
curves. The results were represented as mean ± SD.
Data analysis and statistics
The MS/MS data were searched automatically against
the international protein index (IPI)human database [11]
using the Spectrum Mill Proteomics Workbench soft-
ware (RevA.03.03, Agilent, USA). Only peptides with
Spectrum Mill score more than 8 and Spectrum Mill
Scored Peak Intensity(SPI) > 70% were considered posi-
tives. The confidence of all identified proteins must
have more than 95%. In addition, protein with p-value <
0.05 was considered as significant. After each protein
was identified, the relative abundance of protein in the
sample was quantified by recording the mean of the
peak intensities(MPI) of the component peptides [12].
The quantitative results were analyzed by one way ana-
lysis of variance followed by the Tukey test after confir-
mation of normal distribution of the data (data are
presented as means ± SD) or by Kruskal-Wallis analysis
of variance on ranks followed by the Dunn’st e s tw h e n
t h ed a t aa r en o tn o r m a l l yd i s t r i b u t e d .AP ≤ 0.05 was
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formed via the SigmaStat software (Systat Software, Inc.,
P o i n tR i c h m o n d ,C A )[ 1 3 ] .G e n eO n t o l o g y( G O )a n a l y -
sis was done by using Expression Analysis Systematic
Explorer (EASE) software [14]. A protein-protein inter-
action network on metabolism was done by download-
ing pathway data from Kyoto Encyclopedia of Genes
and Genomes(KEGG) database, and then enzyme-
enzyme interaction (ECrel) and protein-protein interac-
tion (PPrel) was analyzed by KEGGSOAP software [15].
Finally, the network of relationship between protein to
protein was built and brought forth by Medusa software
[16]. The network was graphically visualized as nodes
(proteins) and edges (the relationships between
proteins).
Results and discussion
Clinical data and high-abundant protein removal
Since all hearts in our study did not have obvious car-
diac injury history, serum cTnI in all patients was nega-
tive and serum CK-MB was within normal limits. Table
1 lists the clinical characteristics. Proteomic analysis of
isolated perfused organ effluent with less blood is a
novel model for protein biomarker discovery [7]. How-
ever, the residual high-abundant plasma proteins such
as albumin, immunoglobulin, transferrin, haptoglobin
and antitrypsin were still present in the effluent. We
removed these residual plasma proteins from effluents
by using Multiple Affinity Removal Column Hu-6HC
before proteomic analysis, and finally none of them was
identified by HPLC-Chip-MS system. This process made
the detection of low abundant proteins easier. The chro-
matogram of the affinity removal of high-abundant pro-
teins is shown in Figure 1.
Protein identification by HPLC-Chip-MS system
Biomarkers are often in low abundance and very diffi-
cult to be identified by using conventional proteomic
approaches. HPLC-Chip-MS method used in our study
has been proved to be a valuable tool for identifying
protein biomarkers with high sensitivity and reproduci-
bility, even for proteins expressed in very low abun-
dances [17]. Total 618 proteins were identified and
among of them, highly reliable proteins are 196 (listed
its source, function, and molecular weight in Additional
file 1). A 29 kDa unknown protein (IPI00877674) was
identified and expressed mostly at myocardium by
immunohistochemistry (data not shown). The molecular
weight (Mr) and isoelectric point(pI)distribution of
highly reliable proteins are shown in Figure 2. These
proteins all showed a fairly wide pI (4.09-11.7) distribu-
tion (Figure 2A), and most of them(73.9%) are smaller
than 70 kDa (Figure 2B). Longer durations of ischemia,
increased the number of identified proteins (Figure 3).
107 proteins were identified at the beginning of ische-
mia, 174 and 175 proteins were identified, respectively,
at 30 min and 60 min after the onset of ischemia (listed
in Additional file 2).
With exception of cardiac troponin I and T, many
known clinic markers for myocardial ischemia and
Figure 1 Chromatogram of the affinity removal of high-
abundant proteins from the effluent. Injections of 75 ul of 4 ×
diluted effluent in buffer A were made on a Multiple Affinity
Removal Column (4.6 × 50 mm) at a flow rate of 0.25 ml/min in
buffer A. Flow-through fractions were collected from 1.5 - 4.5 min.
The bound fraction was eluted with buffer B at a flow rate of 1.0
ml/min for 3.5 min.
Figure 2 Molecular weight and pI distribution of proteins
identified consistently in five hearts’ effluents. A. Presented was
pI distribution of identified proteins. B. Presented was molecular
masses distribution of identified proteins.
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study, such as aspartate aminotransferase (ASA), CK-
MB, heart-type fatty acid-binding protein (H-FABP), lac-
tate dehydrogenase B (LDHB), and myohemoglobin
(MB) (Table 2). However, we did not detect ischemia
modified albumin in the effluents, the biomarker for
early myocardial ischemia, nor did Koomen et al in a
rat model [7]. This protein were not detected possibly
because of the removal of albumin by multiple affinity
removal system in our study. In addition, five additional
proteins specific to heart or muscle were identified: car-
diac alpha actin, isoform alpha-enolase of alpha-enolase
(ENO1), phosphoglycerate mutase 2 (PGAM2), isoform
M1 of pyruvate kinase isozymes M1/M2(PKM2) and
isoform 8 of Titin. Neither cTnI nor cTnT were
detected possibly because of the lower level of cTnI and
cTnT release with mild ischemic injury of myocardium,
their late release, or few detectable peptides for them
after use of tryptic digestion. Four proteins expressed
abundantly in heart were identified including Cysteine-
rich protein 2,S100 calcium binding protein A1, 14 kDa
phosphohistidine phosphatase and mesenchymal stem
cell protein DSC92. In additional, those identified pro-
teins including Glucose-6-phosphate isomerase (GPI),
Creatine kinase M-type (CKM), Malate dehydrogenase
(MDH1), Creatine kinase B-type (CKB), (heart-type)
Fatty acid-binding protein (FABP3), Glycerol-3-phos-
phate dehydrogenase [NAD+](GPD1), PGAM2, MB,
Superoxide dismutase(SOD1), Adenylate kinase 1(AK1),
Isoform 1 of Triosephosphate isomerase(TPI1), Phos-
phatidylethanolamine-binding protein 1(PEBP1), Glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH),
Aspartate aminotransferase,(GOT1) and Four and a half
LIM domains 1 variant(FHL1) were also detected in cor-
onary sinus plasma of planned myocardial infarction
patients by Addona et al [18].
Figure 3 The relationship between the number of proteins
identified by HPLC-Chip-MS system and ischemic time. Longer
durations of ischemia increased the number of identified
proteins.107 proteins were identified at the beginning of ischemia,
174 and 175 proteins were identified respectively at 30 min and 60
min after the onset of ischemia.
Table 2 Part of the identified proteins that may be interesting in potential biomarker discovery of early ischemia in
myocardium
Protein name Function Distinct peptide MW(Da) Organ specific Clinical marker
Isoform M1 of Pyruvate kinase isozymes M1/M2 metabolism 12 58,062.4 yes yes
Actin, alpha cardiac muscle 1 cytoskeleton 8 42,019.2 yes
Aspartate aminotransferase 1 metabolism (amino acid) 6 46,247.7 yes
Creatine kinase M-type energ transduction 15 43,101.4 yes yes
Heart -fatty acid-binding protein, lipid transport 9 14,858.1 yes yes
Glyceraldehyde-3-phosphate dehydrogenase metabolism (glycolysis) 14 36,053.4
L-lactate dehydrogenase B chain metabolism (glycolysis) 14 36,638.7 yes yes
Myoglobin oxygen transport 17 17,183.9 yes yes
Isoform 1 of Triosephosphate isomerase metabolism (glycolysis) 12 30,791.2
Isoform 8 of Titin cytoskeletal activity 4 3829,893.5 yes
Glucose-6-phosphate isomerase metabolism (glycolysis) 5 63147.5
Isoform 1 of Gelsolin cytoskeletal activity 9 85697.9
Phosphoglycerate mutase 2 metabolism (glycolysis) 2 28766.3 yes
Adipocyte -fatty acid-binding protein lipid transport 9 14719
Adenylate kinase 1 ATP regeneration 5 23410.9
Creatine kinase B-type kinase activity 2 42644.5
Four and a half LIM domains 1 variant protein binding 5 33578.9
Malate dehydrogenase, cytoplasmic metabolism (glycolysis) 12 36426.3
Phosphatidylethanolamine-binding protein 1 protease inhibitor 8 21056.9
PGM1 65 kDa protein magnesium ion binding 3 64560.9
Superoxide dismutase oxidoreductase 1 15935.8
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Spectrum Mill software according to MPI of the compo-
nent peptides. Trends in MPI of proteins matched by
database searches can be used to determine which pro-
teins were released from the tissue. For examples, the
MPI of the plasma proteins, such as hemoglobin, fol-
lowed a gradually decreasing trend as they were
r e m o v e da w a yf r o mt h eb l o o dv e s s e lb yp e r f u s i o nw i t h
crystalloid solution (Figure 4A). The MPI of LDHB indi-
cates the increasing trend for proteins released from the
heart (Figure 4B). The quantitative results showed that
there were six proteins released from the heart when
ischemic time was increasing, including LDHB, glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH), glucose-
6-phosphate isomerase (GPI), PGAM2, gelsolin and iso-
form 8 of titin (Figure 5). Four of these six proteins are
glycolytic enzymes, including LDHB, GAPDH, GPI,
PGAM2, and two of them (gelsolin and isoform 8 of
titin) are targets of matrix metalloproteinase (MMP),
which will be activated during myocardial ischemia/
reperfusion injury [19-22]. Isoform 8 of titin is specifi-
cally expressed in cardiac muscle with a large molecular
weight (~3800 kDa) and is very important in the con-
traction of striated muscle tissues. It is unclear how iso-
form 8 of titin was released into the effluent during
myocardial ischemia. Ali et al reported that titin was
degraded by MMP-2 during myocardial ischemia/reper-
fusion injury [21]. Thus, those degradation products of
titin could be released from myocardial cells and be
detected in the effluent.
Figure 4 The relationship between the mean of peak intensities
(MPI) and ischemic time. A. Presented was the relationship between
the mean of peak intensities and ischemic time in hemoglobin. B.
Presented was the relationship between the mean of peak intensities
and ischemic time in L-lactate dehydrogenase B.
Figure 5 Six proteins released significantly into the effluents during myocardial ischemia by quantitative analysis of the mean of the
peak intensities (MPI). A. The MPI of L-lactate dehydrogenase B (LDHB). B. The MPI of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). C.
The MPI of glucose-6-phosphate isomerase (GPI). D. The MPI of phosphoglycerate mutase 2 (PGAM2). E. The MPI of gelsolin. F. The MPI of
isoform 8 of titin. Among them, LDHB, GAPDH, GPI and PGAM2 are glycolytic enzymes. Gelsolin and isoform 8 of titin are targets of matrix
metalloproteinase (MMP). Value are expressed as means ± SEM for each group. #p < 0.05 represents a significant difference in the ischemia for
30 min and ischemia for 60 min group compared with the ischemia for 0 min group; ^p < 0.05 represents a significant difference in the
ischemia for 60 min group compared with the ischemia for 30 min group.
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little change in the effluent when the myocardium was
undergoing ischemia. These proteins are MB, H-FABP,
a l p h aa c t i n ,C K - M ,E N O 1 ,P K M 2( F i g u r e6 ) .B u tm a n y
of them showed a rising trend. On the hand, those pro-
teins may not be released into the effluent significantly
because of a mild ischemic injury under hypothermia.
Under this condition, myocardium may be undergone a
reversible cellular damage, such as myocardial stunning
or hibernation, rather than an irreversible cellular
damage, such as myocardial infarction [23,24]. These
markers for myocardial infarction detected in the efflu-
ent, including MB and CK-MB may be released into the
blood due to myocardial injury by surgery procedure or
ischemia before our measurement. On the other hand,
the number of samples is not big enough in this study.
Further researches will be needed to test this issue.
Comfirmation of protein expression by ELISA
To quantify the expression of some identified proteins,
samples were further examined by ELISA. The concen-
trations of LDHB and PGAM2 showed an increasing
trend in effluent samples of perfused heart when
ischemic time was extending. The mean concentrations
of LDHB at ischemia for 30 min and at ischemia for
60 min were approximately 1.5-fold higher and 1.9-
fold higher than at ischemia for 0 min respectively
(Figure 7A), whereas the mean concentrations of
PGAM2 were approximately 1.8-fold higher at ische-
mia for 30 min and 2.8-fold higher at ischemia for 60
min than at ischemia for 0 min(Figure 7B). But the
mean concentration of Titin was almost no change
w h i l ei s c h e m i ct i m ew a si n c r e a s i n g( F i g u r e7 C ) .I t ’s
unclear what happened on it. Maybe the antibody of
titin in the ELISA kit is unable to combine with iso-
form 8 of titin specifically, or the antigenic epitope for
anti-titin was destroyed after titin was degraded by
MMP-2 and released from myocardial cells [21]. As a
biomarker of myocardial infarction, LDHB was
identified by MS in our study, so did by Koomen JM
et al with the same perfused heart effluent model as
ours [7]. HPLC-Chip-MS method is more sensitive
than clinical assay and the component of the effluent
sample is much simpler than that of plasma, so LDHB
could be detected sensitively in our study even if a few
of cardiac cells are damaged by ischemia.
GO analysis
The biological functions of the identified proteins were
diverse. However, a large percentage could be related to
the heart function during ischemia and reperfusion:
ATP regeneration, metabolism (in particular glycolysis),
oxidative stress response and protective proteins. 33% of
the identified proteins were involved in the metabolic
Figure 6 Six proteins specific to heart had little change in the
effluents during myocardial ischemia by quantitative analysis
of the mean of the peak intensities (MPI). A. The MPI of MB.B.
The MPI of H-FABP. C. The MPI of alpha actin. D. The MPI of CK-M.
E. The MPI of ENO1. F. The MPI of PKM2.
Figure 7 Comfirmation of protein expression by ELISA.T h e
concentration of three interesting proteins was quantitatively
determinated with ELISA kits(n = 5). A. The mean concentration of
LDHB.B. The mean concentration of PGAM2. C. The mean
concentration of Titin. Value are expressed as means ± SEM for each
group. #p < 0.05 represents a significant difference in the ischemia
for 60 min group compared with the ischemia for 0 min group.
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were involved in stress process and 9% were respectively
involved in regulation of apoptosis and acute inflamma-
tory response (Figure 8A). Only 31% were plasma pro-
t e i n s ;t h er e s tw e r ef r o mf r o mav a r i e t yo fc e l l u l a r
organelles(28%) and the other cellular components(41%)
(Figure 8B). A large percentage of identified proteins
could be related to enzyme regulation (10%), signal
transduction (7%), transporter (6%) and cytoskeletal
activity (5%)(Figure 8C).
Figure 8 Gene Ontology classification generated by Software Tool for Researching Annotations of Proteins. Pie charts showing the
classification of the identified proteins according to their biological functions, cellular component and molecular function. A. The biological
functions of the identified proteins were diverse. However, a large percentage of them are related to the heart function during ischemia and
reperfusion: ATP regeneration, metabolism (in particular glycolysis), oxidative stress response and protective proteins. 33% of the identified
proteins were involved in the metabolic process for carbohydrate (22%) and alcohol (11%), 28% were involved in stress process and 9% were
respectively involved in regulation of apoptosis and acute inflammatory response (Figure 7A). B. Of the 196 unique proteins identified in these
experiments, only 31% were plasma proteins. The remainders were from the cellular organelles (28%) as well as a variety of other cellular
components(41%). C. The molecular functions of the identified proteins were diverse, but a large percentage could be related to enzyme
regulation (10%), signal transduction (7%), transporter (6%), cytoskeletal activity (5%).
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After myocardial ischemia, more than twenty proteins
involving in metabolism were identified by HPLC-Chip-
MS system. To evaluate the eventual correlation existing
between these identified proteins, the network analysis
on metabolism was performed by KEGGSOAP software.
Known interactions coming from KEGG interaction
databases were graphically visualized as nodes and
edges. The map is shown in Figure 9A. Interestingly,
about 55% of those proteins showing in the network are
Figure 9 The protein-protein interaction network on myocardial metabolism. A. protein-protein interaction network on metabolism was
done by downloading pathway data from Kyoto Encyclopedia of Genes and Genomes(KEGG) database, then enzyme-enzyme interaction (ECrel)
and protein-protein interaction (PPrel) was analyzed by KEGGSOAP software. Finally, the network of relationship among proteins was built and
brought forth by Medusa software. The network was graphically visualized as nodes and edges. Pink lines indicate connections confirmed
experimentally by other researches, blue lines indicate connections derived from databases and yellow lines indicate connections compiled from
co-citation data from literature mining PubMed abstracts. Interestingly, about 55% of those proteins showing in the network are involved in
glycolysis. B. The number of connections of each protein was calculated. ENO1, TPI1 and GAPDH are central “functional hubs” in the map with
more connections than other proteins. They are all important glycolytic enzymes in myocardium.
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Page 9 of 11involved in glycolysis. The number of connections of
each protein was calculated. ENO1, TPI1 and GAPDH
are central “functional hubs” in the map with more con-
nections than other proteins, which have been exten-
sively reported to take part in glycolysis in myocardium.
T h ed e g r e eo fc o n n e c t i o ni ss h o w ni nF i g u r e8 B .I n
order to adapt to oxygen deprivation, myocardial cells
will reprogram their metabolism induced by the PHD/
HIF system and glycolytic enzymes will be expressed
during ischemia [25]. Thus, many glycolytic enzymes
will be expressed and could be released from myocardial
cells during early ischemia, such as L-LDH, GAPDH,
GPI and PGAM2. Type-M of PGAM2 is specifically
expressed in muscles and could be a potential biomarker
for early myocardial ischemia.
Conclusion
In this study, we analyzed low-abundance proteins from
effluents of perfused human hearts after mild ischemic
injury by HPLC-Chip-MS system. Many known clinic
markers for myocardial ischemia, proteins specific to
heart and glycolytic enzymes were among the proteins
identified. Among them, four glycolytic enzymes, L-
LDH, GAPDH, GPI, PGAM2, and two targets of MMP,
gelsolin and isoform 8 of titin, are significantly released
into the effluent during myocardial ischemia. They are
potential biomarkers for mild ischemic injury in myo-
cardium, especially isoform 8 of titin and M-type of
PGAM2, which are more specific for cardiac tissue.
Furthermore, the results of gene network analysis for
metabolism show glycolysis is one of the important con-
versions during early ischemia in myocardium. This
finding may provide new insight into pathology and
biology of myocardial ischemia, and potential diagnostic
and therapeutic biomarkers.
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Additional file 1: Total 196 proteins(2003-2007). Total 196 high
reliable unique proteins were listed with its source, function, and
molecular weight.
Additional file 2: Proteins identified by different ischemic time
(2003-2007). 107 proteins were identified at the beginning of ischemia,
174 and 175 proteins were identified respectively at ischemia for 30 min
and ischemia for 60 min.
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